Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Frequently asked questions
What sector does Centessa Pharmaceuticals PLC ADR (CNTA) operate in?
Centessa Pharmaceuticals PLC ADR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Centessa Pharmaceuticals PLC ADR (CNTA) current stock price?
As of the latest data, Centessa Pharmaceuticals PLC ADR stock price is $40.50, with a previous close of $40.50.
What is Centessa Pharmaceuticals PLC ADR (CNTA) current market capitalization?
Centessa Pharmaceuticals PLC ADR market cap is approximately 6.27 billion.
What is Centessa Pharmaceuticals PLC ADR (CNTA) Earnings Per Share (EPS)?
The trailing EPS is -$1.78, and the forward EPS is -$1.78.
What is Centessa Pharmaceuticals PLC ADR (CNTA) EBITDA?
Centessa Pharmaceuticals PLC ADR EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -75.43 million.
Does Centessa Pharmaceuticals PLC ADR (CNTA) pay dividends?
No. Centessa Pharmaceuticals PLC ADR does not pay a dividend.
What is Centessa Pharmaceuticals PLC ADR (CNTA) beta (volatility) score?
Centessa Pharmaceuticals PLC ADR has a beta of 1.121, meaning its volatility is roughly in line with the market.
